seqirus vaccines holdings limited
seqirus vaccines holdings limited Company Information
Company Number
04679458
Next Accounts
5 days late
Shareholders
seqirus limited
Group Structure
View All
Industry
Activities of head offices
Registered Address
point, 29 market street, maidenhead, berkshire, SL6 8AA
seqirus vaccines holdings limited Estimated Valuation
Pomanda estimates the enterprise value of SEQIRUS VACCINES HOLDINGS LIMITED at £0 based on a Turnover of £0 and 0.49x industry multiple (adjusted for size and gross margin).
seqirus vaccines holdings limited Estimated Valuation
Pomanda estimates the enterprise value of SEQIRUS VACCINES HOLDINGS LIMITED at £0 based on an EBITDA of £0 and a 3.89x industry multiple (adjusted for size and gross margin).
seqirus vaccines holdings limited Estimated Valuation
Pomanda estimates the enterprise value of SEQIRUS VACCINES HOLDINGS LIMITED at £289.8m based on Net Assets of £137.6m and 2.11x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Seqirus Vaccines Holdings Limited Overview
Seqirus Vaccines Holdings Limited is a live company located in berkshire, SL6 8AA with a Companies House number of 04679458. It operates in the activities of head offices sector, SIC Code 70100. Founded in February 2003, it's largest shareholder is seqirus limited with a 100% stake. Seqirus Vaccines Holdings Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Seqirus Vaccines Holdings Limited Health Check
Pomanda's financial health check has awarded Seqirus Vaccines Holdings Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Seqirus Vaccines Holdings Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (108)
- Seqirus Vaccines Holdings Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Seqirus Vaccines Holdings Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Seqirus Vaccines Holdings Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.1%, this is a lower level of debt than the average (56%)
- - Seqirus Vaccines Holdings Limited
- - Industry AVG
SEQIRUS VACCINES HOLDINGS LIMITED financials
Seqirus Vaccines Holdings Limited's latest turnover from June 2023 is 0 and the company has net assets of £137.6 million. According to their latest financial statements, we estimate that Seqirus Vaccines Holdings Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | -200,178,000 | -384,000 | 44,000 | 156,000 | -394,000 | |||||||||
| Operating Profit | -67,000 | -140,984,000 | 200,178,000 | 384,000 | -44,000 | -156,000 | 394,000 | |||||||
| Interest Payable | 7,770,000 | 45,264,000 | 47,227,000 | 101,378,000 | 47,227,000 | 47,227,000 | ||||||||
| Interest Receivable | 310,091,000 | 39,000 | ||||||||||||
| Pre-Tax Profit | 150,100,000 | -67,000 | -148,754,000 | 154,914,000 | -46,843,000 | 208,669,000 | -47,383,000 | -46,794,000 | ||||||
| Tax | 104,000 | 45,000 | 189,000 | -2,646,000 | 2,219,000 | 10,186,000 | 13,373,000 | 13,866,000 | 10,229,000 | |||||
| Profit After Tax | 150,100,000 | 104,000 | 45,000 | 122,000 | -151,400,000 | 157,133,000 | -36,657,000 | 222,042,000 | -33,517,000 | -36,565,000 | ||||
| Dividends Paid | 136,900,000 | |||||||||||||
| Retained Profit | 13,200,000 | 104,000 | 45,000 | 122,000 | -151,400,000 | 157,133,000 | -36,657,000 | 222,042,000 | -33,517,000 | -36,565,000 | ||||
| Employee Costs | ||||||||||||||
| Number Of Employees | 4 | 4 | 4 | 4 | ||||||||||
| EBITDA* | -67,000 | -140,984,000 | 200,178,000 | 384,000 | -44,000 | -156,000 | 394,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 305,751,000 | 305,751,000 | 305,751,000 | 242,200,000 | 242,200,000 | |||||
| Intangible Assets | ||||||||||||||
| Investments & Other | 137,600,000 | 137,600,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 305,751,000 | 305,751,000 | 305,751,000 | 242,200,000 | 242,200,000 |
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 137,600,000 | 137,600,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 137,559,000 | 305,751,000 | 305,751,000 | 305,751,000 | 242,200,000 | 242,200,000 |
| Stock & work in progress | ||||||||||||||
| Trade Debtors | ||||||||||||||
| Group Debtors | 100,000 | 6,100,000 | 6,118,000 | 6,118,000 | 6,036,000 | 6,036,000 | 6,036,000 | 5,991,000 | 5,802,000 | 6,923,000 | 25,815,000 | 14,035,000 | 54,151,000 | 19,382,000 |
| Misc Debtors | 7,101,000 | 11,805,000 | 13,329,000 | 13,991,000 | 95,504,000 | |||||||||
| Cash | 70,000 | 18,000 | 11,000 | |||||||||||
| misc current assets | ||||||||||||||
| total current assets | 100,000 | 6,100,000 | 6,118,000 | 6,118,000 | 6,036,000 | 6,036,000 | 6,036,000 | 5,991,000 | 5,802,000 | 14,024,000 | 37,620,000 | 27,434,000 | 68,160,000 | 114,897,000 |
| total assets | 137,700,000 | 143,700,000 | 143,677,000 | 143,677,000 | 143,595,000 | 143,595,000 | 143,595,000 | 143,550,000 | 143,361,000 | 319,775,000 | 343,371,000 | 333,185,000 | 310,360,000 | 357,097,000 |
| Bank overdraft | ||||||||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | ||||||||||||||
| Group/Directors Accounts | 100,000 | 19,300,000 | 420,000,000 | 43,931,000 | 524,749,000 | |||||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 19,314,000 | 19,314,000 | 19,314,000 | 29,247,000 | 130,330,000 | 130,241,000 | 83,398,000 | 282,615,000 | 295,835,000 | |||||
| total current liabilities | 100,000 | 19,300,000 | 19,314,000 | 19,314,000 | 19,314,000 | 449,247,000 | 174,261,000 | 654,990,000 | 83,398,000 | 282,615,000 | 295,835,000 | |||
| loans | 19,292,000 | 19,292,000 | 19,314,000 | 300,000,000 | 524,749,000 | 524,749,000 | 524,749,000 | |||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | ||||||||||||||
| provisions | ||||||||||||||
| total long term liabilities | 19,292,000 | 19,292,000 | 19,314,000 | 300,000,000 | 524,749,000 | 524,749,000 | 524,749,000 | |||||||
| total liabilities | 100,000 | 19,300,000 | 19,292,000 | 19,292,000 | 19,314,000 | 19,314,000 | 19,314,000 | 19,314,000 | 449,247,000 | 474,261,000 | 654,990,000 | 608,147,000 | 807,364,000 | 820,584,000 |
| net assets | 137,600,000 | 124,400,000 | 124,385,000 | 124,385,000 | 124,281,000 | 124,281,000 | 124,281,000 | 124,236,000 | -305,886,000 | -154,486,000 | -311,619,000 | -274,962,000 | -497,004,000 | -463,487,000 |
| total shareholders funds | 137,600,000 | 124,400,000 | 124,385,000 | 124,385,000 | 124,281,000 | 124,281,000 | 124,281,000 | 124,236,000 | -305,886,000 | -154,486,000 | -311,619,000 | -274,962,000 | -497,004,000 | -463,487,000 |
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | -67,000 | -140,984,000 | 200,178,000 | 384,000 | -44,000 | -156,000 | 394,000 | |||||||
| Depreciation | ||||||||||||||
| Amortisation | ||||||||||||||
| Tax | 104,000 | 45,000 | 189,000 | -2,646,000 | 2,219,000 | 10,186,000 | 13,373,000 | 13,866,000 | 10,229,000 | |||||
| Stock | ||||||||||||||
| Debtors | -6,000,000 | -18,000 | 82,000 | 45,000 | 189,000 | 5,802,000 | -23,596,000 | 10,256,000 | -40,778,000 | -46,744,000 | 114,886,000 | |||
| Creditors | ||||||||||||||
| Accruals and Deferred Income | -19,314,000 | -9,933,000 | 29,247,000 | 89,000 | 46,843,000 | -199,217,000 | -13,220,000 | 295,835,000 | ||||||
| Deferred Taxes & Provisions | ||||||||||||||
| Cash flow from operations | 6,000,000 | 18,000 | 22,000 | -19,314,000 | -10,000,000 | -120,185,000 | 226,082,000 | 47,157,000 | -145,110,000 | 47,234,000 | 191,572,000 | |||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 41,000 | 137,559,000 | 63,551,000 | 242,200,000 | ||||||||||
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | -19,200,000 | 19,300,000 | -420,000,000 | 420,000,000 | -480,818,000 | 524,749,000 | ||||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | -19,292,000 | -22,000 | 19,314,000 | 300,000,000 | -524,749,000 | 524,749,000 | ||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | ||||||||||||||
| share issue | ||||||||||||||
| interest | -7,770,000 | -45,264,000 | -47,227,000 | 208,713,000 | -47,227,000 | -47,188,000 | ||||||||
| cash flow from financing | -19,200,000 | 23,000 | -22,000 | 19,314,000 | 10,000,000 | 257,744,000 | -226,082,000 | -47,227,000 | 208,713,000 | -47,227,000 | 50,639,000 | |||
| cash and cash equivalents | ||||||||||||||
| cash | -70,000 | 52,000 | 7,000 | 11,000 | ||||||||||
| overdraft | ||||||||||||||
| change in cash | -70,000 | 52,000 | 7,000 | 11,000 |
seqirus vaccines holdings limited Credit Report and Business Information
Seqirus Vaccines Holdings Limited Competitor Analysis
Perform a competitor analysis for seqirus vaccines holdings limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in SL6 area or any other competitors across 12 key performance metrics.
seqirus vaccines holdings limited Ownership
SEQIRUS VACCINES HOLDINGS LIMITED group structure
Seqirus Vaccines Holdings Limited has 1 subsidiary company.
Ultimate parent company
CSL LTD
#0019765
2 parents
SEQIRUS VACCINES HOLDINGS LIMITED
04679458
1 subsidiary
seqirus vaccines holdings limited directors
Seqirus Vaccines Holdings Limited currently has 3 directors. The longest serving directors include Mr John Levy (Feb 2016) and Mr Nigel Hilton (Apr 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr John Levy | England | 65 years | Feb 2016 | - | Director |
| Mr Nigel Hilton | 60 years | Apr 2019 | - | Director | |
| Mr Christopher Thorpe | England | 47 years | Aug 2024 | - | Director |
P&L
June 2023turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
137.6m
+0.11%
total assets
137.7m
-0.04%
cash
0
0%
net assets
Total assets minus all liabilities
seqirus vaccines holdings limited company details
company number
04679458
Type
Private limited with Share Capital
industry
70100 - Activities of head offices
incorporation date
February 2003
age
22
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
June 2023
previous names
novartis vaccines holdings limited (November 2015)
chiron vaccines holdings limited (February 2014)
See moreaccountant
-
auditor
ERNST & YOUNG LLP
address
point, 29 market street, maidenhead, berkshire, SL6 8AA
Bank
-
Legal Advisor
-
seqirus vaccines holdings limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to seqirus vaccines holdings limited.
seqirus vaccines holdings limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for SEQIRUS VACCINES HOLDINGS LIMITED. This can take several minutes, an email will notify you when this has completed.
seqirus vaccines holdings limited Companies House Filings - See Documents
| date | description | view/download |
|---|
